In the past 21 months, Amgen's recently approved products in the U.S. included IMLYGIC (in October 2015), Repatha ( September 2015), Corlanor (April 2015), and BLINCYTO (December 2014).

Newer products like cardiology drug Repatha and immunology drug Tezspire (approved in December 2021) are poised to be top products by 2030, in addition to Lumakras (approved in May 2021).

Amgen Inc. said it had agreed to sell two of its smaller drugs and license a third to Swedish drugmaker Biovitrum AB in a deal valued at $130 million.

Much of the boost can be attributed to sales of products acquired in Amgen’s $27.8 billion buyout of Horizon Therapeutics, which was completed early in the fourth quarter of last year. Assets ...

“In our opinion, Amgen’s fundamentals have never been stronger,” said Wang, who has a $100 12-month target price for Amgen shares, which were trading around $80 on Dec. 6.

Amgen posted 11% revenue growth in the fourth quarter, with at least double-digit growth from ten products. The biotechnology company on Tuesday reported a profit of $627 million, or $1.16 a share ...

The shortfall for the Horizon products came during a quarter in which most of the company’s other treatments exceeded expectations. In fact, Amgen’s overall revenue of $8.1 billion was a 9% ...

WASHINGTON—The Federal Trade Commission said Friday it had agreed to end its legal challenge of drugmaker Amgen ’s AMGN 0.60% $27.8 billion deal to buy Horizon Therapeutics, averting a trial ...

Last Updated: Aug. 29, 2023 at 3:22 p.m. ET First Published: Aug. 29, 2023 at 7:50 a.m. ET ...

Second, Amgen would probably have to avoid buying a smaller company that has products without solid competition to reduce the chances of another FTC action. Still, Amgen's prospects aren't nearly ...